David Altshuler, EVP, Global Research and CSO at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 6,004 shares at $421.77 ($2.5M) on 2024-02-21, disclosed to the SEC on 2024-02-23.
Scheduled sale ($2.5M) by EVP, Global Research and CSO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $421.77 | 3,002 | $1.3M | 50.0% |
| 2 | $421.77 | 3,002 | $1.3M | 50.0% |
| Total | $421.77 avg | 6,004 | $2.5M | 100% |
| Filing → |
| VRTX | SELL | 2025-03-12 | $1.6M | — | Filing → |
| VRTX | SELL | 2025-03-05 | $1.6M | — | Filing → |
| VRTX | SELL | 2025-02-28 | $611K | — | Filing → |